Merck announced the U.S. Food and Drug Administration has accepted for priority review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy as treatment with definitive intent for newly diagnosed patients with high-risk locally advanced cervical cancer.
